- Alumis (ALMS) and ACELYRIN (SLRN, Financial) announce amended merger agreement with an updated exchange ratio.
- The merger creates a clinical-stage immunology company with a diversified portfolio and a pro forma cash position of $737 million.
- Transaction supported by a significant percentage of stockholders and expected to close in Q2 2025.
Alumis Inc. (ALMS) and ACELYRIN Inc. (SLRN) have announced an amended merger agreement that adjusts the exchange ratio to 0.4814 shares of Alumis common stock for each share of ACELYRIN. This revision results in Alumis stockholders holding approximately 52% and ACELYRIN stockholders holding 48% of the combined entity.
The merger aims to establish a leading clinical-stage immunology company with a strong and diverse portfolio. The combined company will have a pro forma cash position of approximately $737 million as of December 31, 2024, providing financial runway to support operations and multiple planned clinical trial readouts into 2027.
The transaction has garnered significant support from stockholders, with 62% of Alumis voting shares and 24% of ACELYRIN shares in favor. Both companies are set to hold Special Meetings of Stockholders on May 13, 2025, with the transaction anticipated to close in the second quarter of 2025, pending stockholder approval and customary closing conditions.
This agreement addresses feedback from ACELYRIN shareholders regarding value creation and is designed to maximize long-term potential by bringing together robust resources and complementary pipelines. The merger is expected to enhance financial flexibility and advance multiple late-stage clinical programs efficiently.
